LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting ...

Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, "Our ongoing first-in-human study, LIBERATE-1, remains on track to deliver key data in mid-2025 with the aim of validating our ...

Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight subjects.

Vivani Medical's CEO presents on drug delivery advancements at AAPS workshop, focusing on improving patient adherence with innovative implants.

Vivani Medical, Inc. (NASDAQ:VANI) and Okava Pharmaceuticals, Inc. expanded their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management ...

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing Vivani Medical, Inc. - GlobeNewswire - Wed Mar 26, 6:30AM CDT ...

--Vivani Medical, Inc., a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal ...

Vivani's lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani's emerging pipeline ...

ALAMEDA, Calif. - Vivani Medical, Inc. (NASDAQ: VANI), a biopharmaceutical company with a market capitalization of $62.2 million, has announced its intention to spin off Cortigent, Inc., its ...

Vivani’s board of directors has authorized management to proceed with a plan to spin off its Cortigent neuromodulation business and Vivani is expected to provide certain transition services.